A Phase I, Two-stage, Multi-center, Open Label, Dose-escalation Study of BKM120 in Combination With Adjuvant Temozolomide and With Concomitant Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Trial Profile

A Phase I, Two-stage, Multi-center, Open Label, Dose-escalation Study of BKM120 in Combination With Adjuvant Temozolomide and With Concomitant Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Buparlisib (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 12 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 04 May 2017 Planned End Date changed from 28 Apr 2017 to 19 May 2017.
    • 04 May 2017 Planned primary completion date changed from 28 Apr 2017 to 19 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top